fluciclovine-f-18 and Oropharyngeal-Neoplasms

fluciclovine-f-18 has been researched along with Oropharyngeal-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for fluciclovine-f-18 and Oropharyngeal-Neoplasms

Article	Year
Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT. Clinical nuclear medicine, 2019, Volume: 44, Issue:5 We present a case of oropharyngeal squamous cell carcinoma (SCC) of the tongue base incidentally detected on F-fluciclovine PET/CT. A 79-year-old man with history of locally advanced prostate cancer (Gleason score 4 + 5 = 9; cT2cN1M0) previously treated with androgen deprivation therapy (luprolide + bicalutamide) presented with a slowly rising serum prostate-specific antigen over 3 years, concerning for recurrent disease. F-fluciclovine PET/CT, obtained to identify potential sites of recurrence, demonstrated prostate bed uptake with possible left seminal vesicle involvement. Additionally, an exophytic, tracer-avid right tongue base mass was incidentally noted and later confirmed to be p16+ SCC on biopsy. Topics: Aged; Carboxylic Acids; Carcinoma, Squamous Cell; Cyclobutanes; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Oropharyngeal Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals	2019
Incidental detection of oropharyngeal cancer with fluciclovine PET. Head & neck, 2019, Volume: 41, Issue:8 Fluorine-18-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (fluciclovine) is a synthetic amino acid radiopharmaceutical initially developed to improve noninvasive diagnosis of gliomas and currently FDA approved for prostate cancer imaging. Although fluciclovine positron emission tomography (PET) has proven to be efficacious in detecting multiple types of cancer, its ability to detect oropharyngeal squamous cell carcinoma (OPSCC) is largely unknown.. We describe a case of incidental OPSCC detection with fluciclovine PET in a 66-year old male patient during workup for recurrent prostate adenocarcinoma.. Fluciclovine PET detected a left base of tongue (BOT) lesion, which was subsequently confirmed as invasive SCC on surgical pathology.. Given these findings, we discuss potential future directions for research with fluciclovine to overcome some of the known limitations of Topics: Aged; Carboxylic Acids; Carcinoma, Squamous Cell; Cyclobutanes; Humans; Incidental Findings; Male; Oropharyngeal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals	2019

Article

Year

Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT.

Clinical nuclear medicine, 2019, Volume: 44, Issue:5

We present a case of oropharyngeal squamous cell carcinoma (SCC) of the tongue base incidentally detected on F-fluciclovine PET/CT. A 79-year-old man with history of locally advanced prostate cancer (Gleason score 4 + 5 = 9; cT2cN1M0) previously treated with androgen deprivation therapy (luprolide + bicalutamide) presented with a slowly rising serum prostate-specific antigen over 3 years, concerning for recurrent disease. F-fluciclovine PET/CT, obtained to identify potential sites of recurrence, demonstrated prostate bed uptake with possible left seminal vesicle involvement. Additionally, an exophytic, tracer-avid right tongue base mass was incidentally noted and later confirmed to be p16+ SCC on biopsy.

Topics: Aged; Carboxylic Acids; Carcinoma, Squamous Cell; Cyclobutanes; Fluorodeoxyglucose F18; Humans; Incidental Findings; Male; Oropharyngeal Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals

2019

Incidental detection of oropharyngeal cancer with fluciclovine PET.

Head & neck, 2019, Volume: 41, Issue:8

Fluorine-18-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (fluciclovine) is a synthetic amino acid radiopharmaceutical initially developed to improve noninvasive diagnosis of gliomas and currently FDA approved for prostate cancer imaging. Although fluciclovine positron emission tomography (PET) has proven to be efficacious in detecting multiple types of cancer, its ability to detect oropharyngeal squamous cell carcinoma (OPSCC) is largely unknown.. We describe a case of incidental OPSCC detection with fluciclovine PET in a 66-year old male patient during workup for recurrent prostate adenocarcinoma.. Fluciclovine PET detected a left base of tongue (BOT) lesion, which was subsequently confirmed as invasive SCC on surgical pathology.. Given these findings, we discuss potential future directions for research with fluciclovine to overcome some of the known limitations of

Topics: Aged; Carboxylic Acids; Carcinoma, Squamous Cell; Cyclobutanes; Humans; Incidental Findings; Male; Oropharyngeal Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals

2019